GLP-1 RAs may reduce adverse effects in morbidly obese TKA patients: Study
A new study published in The Journal of Bone and Joint Surgery showed that when glucagon-like peptide-1 receptor agonist (GLP-1 RAs) are used during total knee arthroplasty (TKA), morbidly obese individuals (BMI ≥40 kg/m2) may experience fewer problems.
The results from weight optimization techniques for patients having total knee arthroplasty who are morbidly obese and have a body mass index (BMI) of ≥40 kg/m2 have been inconsistent. In order to assess the impact of perioperative glucagon-like peptide-1 receptor agonist usage in patients having primary total knee arthroplasty who had a BMI of ≥40 kg/m2, Billy Kim and his colleagues undertook this study.
The participants with morbid obesity going through primary TKA were matched based on their Charlson Comorbidity Index (CCI), age, gender, and diagnosis of type-2 diabetes mellitus. They were stratified into two groups where one used GLP-1 RA for 3 months prior to and following the procedure (treatment group) and the other who did not use it (control group) using an administrative claims database. Furthermore, a cohort of TKA patients with a BMI between 35.0 and 39.9 kg/m2 was compared to these groups. The matched groups were compared in terms of infection, complications, revision, and readmission.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.